ArticlePediatric obesity2026
Starting Age for Screening Metabolic Dysfunction-Associated Steatotic Liver Disease in Children Using Controlled Attenuation Parameter on Transient Elastography.
Article in Pediatric obesity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Amino Acids-Potential Biomarkers of Histological Features for MASLD in Pediatric Obesity.International journal of molecular sciences · 2026Review
- Starting Age for Screening Metabolic Dysfunction-Associated Steatotic Liver Disease in Children Using Controlled Attenuation Parameter on Transient Elastography.Pediatric obesity · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundRising sedentary behaviour and consumption of sugar-sweetened beverages and ultra-processed foods have increased the risk and earlier onset of obesity in children.
objectivesTo define controlled attenuation parameter (CAP) cut-off values in healthy children, assess the prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) in children with overweight and obesity, and establish an appropriate starting age for MASLD screening in our population.
methodsHealthy primary school children were recruited. Hepatic steatosis was assessed using CAP, and body composition data were collected during two periods: August 2020-March 2021 and February 2023-May 2024.
resultsOf 1653 participants (mean age 9.5 ± 1.7 years), 976 children with normal weight were used to establish reference intervals. Hepatic steatosis was defined as a CAP above 247 dB/m (97.5th percentile). The prevalences of MASLD in children with overweight and obesity were 0% and 16%, respectively, in school grade 1, which increased to 19% and 75% in school grade 6 (p < 0.001).
conclusionsScreening for hepatic steatosis associated with obesity should begin as early as school grade 1, while screening for children with overweight may be more appropriate by school grade 6. These findings emphasise the need for age- and weight-specific screening strategies for children with overweight and obesity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.